

July 2018 APC Decisions

| Medicine | Status | Indication | Other Information |
|--|---------|---------------|---|
| Kyleena® (Bayer Plc) IUD | GREEN | Contraception | A low dose levonorgestrel releasing IUD licensed for contraception for up to 5 years use |
| Levosert® (Gedeon Richter (UK) Ltd) IUD | GREEN | Contraception | A levonorgestrel releasing IUD licensed for contraception and Heavy Menstrual Bleeding. When used as an alternative to Mirena®, may offer a cost saving |
| Insulin Degludec (Tresiba®, Novo Nordisk) 100units/ml and 200units/ml Caution when prescribing the high strength | AMBER 2 | Diabetes | Type 2 diabetes as a third line insulin: <ul style="list-style-type: none"> • where existing basal insulin is running out • with poor compliance with the existing regimen • requiring flexibility of administration • with recurrent hypos including nocturnal or requiring high doses of insulin. |
| Fluticasone furoate / umeclidinium (Umec) / vilanterol Trelegy® dry powder inhaler) | AMBER 2 | COPD | For patients who have received a face to face assessment with a respiratory specialist and triple therapy is deemed to be appropriate <ul style="list-style-type: none"> • available in the Elipta device • priced equivalent to Trimbow |
| Formoterol fumarate/ beclometasone dipropionate/ glycopyrronium bromide - (Trimbow® inhaler) | AMBER 2 | COPD | For patients who have received a face to face assessment with a respiratory specialist and triple therapy is deemed to be appropriate <ul style="list-style-type: none"> • available as an MDI • priced equivalent to Trelegy |

For a full explanation of the Traffic Light definitions, please refer to the [Joint Formulary website](#)

News from the APC


Ratified at the meeting:

(Please note the final documents will be uploaded and available on the APC website within the next 2 weeks to allow for final editing)

- **Dementia prescribing information sheets (review)**
- **Opioid in non cancer pain guidelines (review)**
- **Neuropathic pain guidelines (review)**
- **Liothyronine patient information leaflet (new)**
- **Stoma ancillary items formulary (new)**
- **Ferric maltol treatment algorithm (new)**

Self - Care

The [Guidance on conditions for which over the counter items should not routinely be prescribed in primary care](#) was published by NHSE and as such CCGs have been looking at how this advice may be implemented locally.

Look out for our new self care symbol on the Nottinghamshire Formulary - 

This indicates items where it may be appropriate to ask the patient to purchase the product or similar from a pharmacy or supermarket.

Horizon Scanning, Formulary amendments and traffic light changes

Self –care; some items are considered to be inappropriate to be prescribed on the NHS in both primary and secondary care. These have been removed from the formulary:

- ◇ Driclor[®] antiperspirant
- ◇ Migramax[®] and Paramax[®]
- ◇ Proflavin[®] cream

Other formulary changes;

- Probenacid changed from **AMBER 2** to **RED** due to the product becoming unlicensed
- LMX4 lidocaine 4% cream reclassified as **GREEN** in line with other products
- Blephagel[®], Blephasol[®] and Blephaclean[®] classified as **GREY**
- Prednisolone suppositories reclassified as **AMBER 2** in light of increased cost
- Carbocisteine sachets added as **GREEN** as a cost effective alternative
- Trimovate cream reclassified as **AMBER 2** with restrictions in light of increased cost.
- Targinact[®] changed from **AMBER 2** to **GREY**

- ◆ Actipatch[®] added as **GREY**
- ◆ Staglatro[®] (ertugliflozin) added as **GREY**
- ◆ Steglujan[®] (ertugliflozin/sitagliptin) added as **GREY**
- ◆ Segluromet[®] (ertugliflozin/metformin) added as **GREY**
- ◆ Visicare[®] (solifenacin) oral solution added as **GREY**
- ◆ Teduglutide injection added as **GREY**
- ◆ Shingrix[®] (Herpes zoster vaccine) added as **GREY**

Current work in development

- **ADHD shared care protocol update for children and new guidance for adults**
- **Omeprazole liquid flow chart**
- **Benzodiazepine step down guidance**
- **Spacer device formulary**
- **New submission - Mycophenolate and Azathioprine shared care**
- **Formulary review - Quinagolide**
- **Constipation flow chart and pathways**
- **Haematinics Guidelines**
- **Lactose intolerance and cows milk allergy guideline review**

Upcoming NICE guidance

| TITLE | GUIDELINE/TA | EXPECTED DATE |
|---|--------------|----------------|
| Chronic heart failure in adults: diagnosis and management | Guideline | September 2018 |

The work of the NAPC is supported and managed by the interface team below. They can be contacted via MACCG.NottsAPC@nhs.net if you would like to make a submission or have any queries.

Laura Catt, Prescribing Interface Advisor, NHS Mansfield and Ashfield CCG

Lynne Kennell, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Irina Varlan, Specialist Interface and Formulary Pharmacist, Nottingham University Hospitals NHS Trust